Stock Analysis

Is Cencora (NYSE:COR) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. As with many other companies Cencora, Inc. (NYSE:COR) makes use of debt. But is this debt a concern to shareholders?

Advertisement

Why Does Debt Bring Risk?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. The first step when considering a company's debt levels is to consider its cash and debt together.

Check out our latest analysis for Cencora

What Is Cencora's Net Debt?

As you can see below, Cencora had US$4.39b of debt at September 2024, down from US$4.79b a year prior. However, it also had US$3.13b in cash, and so its net debt is US$1.26b.

debt-equity-history-analysis
NYSE:COR Debt to Equity History January 27th 2025

A Look At Cencora's Liabilities

We can see from the most recent balance sheet that Cencora had liabilities of US$54.3b falling due within a year, and liabilities of US$12.0b due beyond that. Offsetting these obligations, it had cash of US$3.13b as well as receivables valued at US$24.0b due within 12 months. So its liabilities outweigh the sum of its cash and (near-term) receivables by US$39.2b.

This deficit is considerable relative to its very significant market capitalization of US$48.2b, so it does suggest shareholders should keep an eye on Cencora's use of debt. This suggests shareholders would be heavily diluted if the company needed to shore up its balance sheet in a hurry.

We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). Thus we consider debt relative to earnings both with and without depreciation and amortization expenses.

Cencora has a low net debt to EBITDA ratio of only 0.30. And its EBIT covers its interest expense a whopping 19.4 times over. So we're pretty relaxed about its super-conservative use of debt. And we also note warmly that Cencora grew its EBIT by 20% last year, making its debt load easier to handle. The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately the future profitability of the business will decide if Cencora can strengthen its balance sheet over time. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So it's worth checking how much of that EBIT is backed by free cash flow. Happily for any shareholders, Cencora actually produced more free cash flow than EBIT over the last three years. That sort of strong cash generation warms our hearts like a puppy in a bumblebee suit.

Our View

Happily, Cencora's impressive interest cover implies it has the upper hand on its debt. But, on a more sombre note, we are a little concerned by its level of total liabilities. It's also worth noting that Cencora is in the Healthcare industry, which is often considered to be quite defensive. Looking at the bigger picture, we think Cencora's use of debt seems quite reasonable and we're not concerned about it. While debt does bring risk, when used wisely it can also bring a higher return on equity. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. To that end, you should be aware of the 3 warning signs we've spotted with Cencora .

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

β€’ Dividend Powerhouses (3%+ Yield)
β€’ Undervalued Small Caps with Insider Buying
β€’ High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NYSE:COR

Cencora

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.

Adequate balance sheet with moderate growth potential.

Advertisement

Weekly Picks

AL
RKLB logo
AlexLovell on Rocket Lab Β·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources Β·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
66 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
FU
FundamentallySarcastic
CCP logo
FundamentallySarcastic on Credit Corp Group Β·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.6410.4% overvalued
11 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Updated Narratives

BO
MU logo
BonSquid88 on Micron Technology Β·

Micron Technology will experience a robust 16.5% revenue growth

Fair Value:US$40021.1% undervalued
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
AMZN logo
MarketMuse on Amazon.com Β·

Amazon will rebound as AI investments start paying off by late 2026

Fair Value:US$45049.7% undervalued
45 users have followed this narrative
2 users have commented on this narrative
0 users have liked this narrative
RO
Robbo
HVN logo
Robbo on Harvey Norman Holdings Β·

Inside Harvey Norman: Asset-Heavy Retail in an Online World

Fair Value:AU$5.8419.5% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources Β·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
66 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab Β·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA Β·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0225.4% undervalued
1011 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative